1988 Fiscal Year Final Research Report Summary
Studies on chemotherapy of advanced or recurrent head and neck cancer for purposes of prolongation of life with improvement of quality of life
| Project/Area Number |
62570784
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Otorhinolaryngology
|
|---|
| Research Institution | Department of Otorhinolaryngology, School of Medicine, Keio University |
|---|
Principal Investigator |
INUYAMA Yukio Department of Otorhinolaryngology, School of Medicine, Keio University, 医学部, 講師 (70051480)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TANAKA Kazuhito Department of Otorhinolaryngology, School of Medicine, Keio University, 医学部, 助手 (30179741)
TOJI Masao Department of Otorhinolaryngology, School of Medicine, Keio University, 医学部, 助手 (60180113)
KAWAURA Mitsuhiro Department of Otorhinolaryngology, School of Medicine, Keio University, 医学部, 助手 (10169675)
|
|---|
| Project Period (FY) |
1987 – 1988
|
| Keywords | Quality of life / Advanced or recurrent cancer of the head and neck / Prolongation of life with chemotherapy alone / Cisplatin / Peplomycin / ペプロマイシン / 非交叉耐性化学療法 |
|---|
| Research Abstract |
1. Fundamental research; We tried to evaluate the effect of combination of carboplatin (CBDCA) and peplomycin (PEP) on experimental study defore applying the combination therapy clinically. Male BALB/c nude mice and three unde mouce-grown squamous cell carcinoma of head and neck origin were used in the present study. The results revealed statistically no different anti-tumor activity between the combination therapies on three nude mouse-grown human squamous cell carcinomas. If so, this combination may be more useful clinically in terms of lower nephrotoxicity resulting in no phdration durig the treatment.
2. Clinical research: In our department, 109 patients with advanced or recurrent head and neck cancer received palliative chemotherapy for the purpose of prolonging life and improving quality of life throughout the past 11 years. Single or combined agents including CDDP, bleomycin analogs, methotrexate, vincristine etc were used. The 5-year survival ratge was 3.3% in this series. We also evaluated the quality of life of all patients receiviving chemotherapy. An improvement of quality of life was observed in 39 of them. The lives of the 30 patients, whose performance status improved after chemotherapy, were prolonged and they enjoyed their home lives while receiving treatment at the outpatient level. The use of chemotherapy at the outpatient level will be increasingly important in the future. From our longtime experiences on chemotherapy of the head and neck cancer, we recognized several combinations in which noncross-resistance was observed. They include UFT+BM therapy (bleomycin, mitomycin C), UFT-M therapy (UFT, mitomycin C) + CP therapy (CDDP, PEP), VMB therapy (vincristine, methotrexate, bleomycin) + CP therapy etc. At present, we recommend noncross-resistant sequential chemotherapy consisting ofm VMP therapy (vincristine, methotrexate,PEP) or VDMP therapy (vindesine, methotrexate, PEP) nad CDDP containing regimen like CP therapy or CDDP + 5-fluorouracil.
|
Research Products
(14 results)
